Leica Biosystems and Florida-based Moffitt Cancer Center, one of the USA’s top cancer hospitals and a leader in cancer research, have announced an expansion of their partnership to accelerate the adoption of digital pathology across the state.
This strategic collaboration marks Florida’s first large-scale implementation of digital pathology technology, aimed at improving speed, precision and access to pathology services.
Building on a successful research initiative using the Aperio GT 450 scanner, Moffitt will deepen its investment in the Aperio GT platform to support broader adoption of digital workflows—bringing innovation to one of the nation’s most impacted regions. Florida ranks third nationwide in projected cancer incidence, with an estimated 162,410 new cases in 2023 alone.
This collaboration also reflects a broader commitment to accelerating innovation in pathology workflows, with the goal of advancing precision medicine. As AI-enabled technologies continue to evolve, digital pathology is increasingly positioned to support scalable, data-driven insights, critical to cancer research and laying the foundation for precision therapies.
“This partnership is transforming how pathology services are delivered,” said William Westra, MD, Vice Chair of Pathology at Moffitt. “Digital pathology enables faster access to expert insights, removes geographic barriers, and supports broader outreach efforts. The success of this initiative has significant implications for improving access to high-quality pathology services across Florida and beyond.”
Moffitt’s pathology department processes more than 1.5 million glass slides annually, reflecting the need for scalable, efficient solutions. As demand for pathology services continues to rise nationwide, digital tools offer a way to meet that need with speed and precision. By removing geographic constraints, digital pathology helps ensure timely and consistent results for more people, including those in underserved regions. Remote reviews can be conducted without compromising quality, supporting broader access to specialized pathology services.
Leica Biosystems, a Danaher company, is a recognized leader in digital pathology. The Aperio GT 450 line offers high-throughput scanning, exceptional image quality and seamless integration, empowering pathology teams to work more efficiently and confidently.
“Leica Biosystems is proud to support Moffitt Cancer Center in expanding digital pathology across Florida,” said Naveen Chandra, VP and GM, Digital Pathology at Leica Biosystems. “Digital pathology is enabling scalable, data-driven insights, and with AI technologies, accelerating innovation. Together, these advancements are laying the groundwork for the next generation of precision medicine and cancer care.”